Intensive Treatment and Stem Cell Transplantation in Chronic Myelogenous Leukemia: Long-Term Follow-UpSimonsson B.a · Öberg G.a · Björeman M.b · Björkholm M.c · Carneskog J.d · Karlsson K.h · Gahrton G.e · Grimfors G.c · Hast R.c · Karle H.m · Linder O.b · Ljungman P.e · Nielsen J.L.k · Nilsson J.f · Löfvenberg E.g · Malm C.h · Olsson K.a · Olsson-Strömberg U.a · Paul C.e · Stenke L.c · Stentoft J.k · Turesson I.i · Udén A.-M.e · Wahlin A.g · Vilén L.j · Weis-Bjerrum O.l
Departments of Medicine and Hematology,aUniversity Hospital, Uppsala, bUniversity Hospital, Örebro, cKarolinska Hospital, Stockholm, dSahlgrenska Hospital, Gothenburg, eHuddinge University Hospital, Huddinge, fRegional Oncologic Center in Uppsala/Örebro, Uppsala, gUniversity Hospital, Umeå, hUniversity Hospital, Linköping, iMalmö University Hospital, Malmö, and jEast Hospital, Gothenburg, Sweden; Departments of Medicine and Hematology, kAmtssygehuset, Århus, and lRigshospitalet and mHerlev Hospital, Copenhagen, Denmark
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
In the present study we combined interferon (IFN) and hydroxyurea (HU) treatment, intensive chemotherapy and autologous stem cell transplantation (SCT) in newly diagnosed chronic myelogenous leukemia patients aged below 56 years, not eligible for allogeneic SCT. Patients who had an HLA-identical sibling donor and no contraindication went for an allogeneic SCT (related donor, RD). After diagnosis, patients not allotransplanted received HU and IFN to keep WBC and platelet counts low. After 6 months patients with Ph-positive cells still present in the bone marrow received 1–3 courses of intensive chemotherapy. Those who became Ph-negative after IFN + HU or after 1–3 chemotherapy courses underwent autologous SCT. Some patients with poor cytogenetic response were allotransplanted with an unrelated donor (URD). IFN + HU reduced the percentage of Ph-positive metaphases in 56% of patients, and 1 patient became Ph-negative. After one or two intensive cytotherapies 86 and 88% had a Ph reduction, and 34 and 40% became Ph-negative, respectively. In patients receiving a third intensive chemotherapy 92% achieved a Ph reduction and 8% became Ph-negative. The median survival after auto-SCT (n = 46) was 7.5 years. The chance of remaining Ph-negative for up to 10 years after autologous SCT was around 20%. The overall survival for allo-SCT RD (n = 91) and URD (n = 28) was almost the same, i.e. ≈60% at 10 years. The median survival for all 251 patients registered was 8 years (historical controls 3.5 years). The role of the treatment schedule presented in the imatinib era is discussed.
© 2005 S. Karger AG, Basel
- Kantarijan HM, Giles FJ, O’Brien SM, Talpaz M: Clinical course and therapy of chronic myelogenous leukemia with interferon-alpha and chemotherapy. Hematol Oncol Clin North Am 1998;12:31–80.
Hehlmann R: Cytostatic therapy in chronic myelogenous leukemia: Review and perspectives; in Huhn D, Hellriegel KP, Niederle N (eds): Chronic Myelocytic Leukemia and Interferon. Berlin, Springer, 1998, pp 102–112.
- Kantarjian HM, Talpaz M, Keating MJ, Estey EH, O’Brien S, Beran M, McCredie KB, Gutterman J, Freireich EJ: Intensive chemotherapy induction followed by interferon-alpha maintenance in patients with Philadelphia chromosome-positive myelogenous leukemia. Cancer 1991;68:1201–1207.
- Thomas ED, Clift RA, Fefer A, Appelbaum FR, Beatty P, Bensinger WI, Buckner CD, Cheever MA, Deeg HJ, Doney K, Fournoy N, Greenberg P, Hansen JA, Martin P, McGuffin R, Ramberg R, Sanders JE, Singer J, Stewart P, Storb R, Sullivan K, Weiden PL, Witherspoon R: Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med 1986;104:155–163.
- Goldman JM, Apperley JF, Jones LM, Marcus RE, Goolden AWG, Batchelor JR, Hale G, Waldmann H, Reid CD, Hows JM, Gordon Smith EC, Catovsky D, Galton DAG: Bone marrow transplantation for patients with chronic myeloid leukemia. N Engl J Med 1986;314:202–207.
- Goldman JM, Gale RP, Horowitz MM, Biggs JC, Champlin RE, Gluckman E, Hoffmann RG, Jacobsen SJ, Marmont AM, McGlave PB, Messner HA, Rimm AA, Rozman C, Speck B, Tura S, Weiner RS, Bortin MM: Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: Increased risk of relapse associated with T-cell depletion. Ann Intern Med 1988;108:806–814.
- Gale RP, Hehlmann R, Zhang MJ, Hasford J, Goldman JM, Heimpel H, Hochhaus A, Klein JP, Kolb HJ, McGlave PB, Passweg JR, Rowlings PA, Sobocinski KA, Horowitz MM: Survival with bone marrow transplantation versus hydroxyurea or interferon for chronic myelogenous leukemia. Blood 1998;91:1810–1819.
Savage DG, Goldman JM: Chronic myelogenous leukemia; in Armitage JO, Antman KH (eds): High Dose Therapy: Pharmacology, Hematopoietins, Stem Cells, ed 3. Baltimore, Williams & Wilkins, 1999, pp 705–731.
- Carella AM, Lerma E, Corsetti MT, Dejana A, Basta P, Vassallo F, Abate M, Soracco M, Benvenuto F, Figari O, Podesta M, Piaggio G, Ferrara R, Sessarego M, Parodi C, Pizzuti M, Rubagotti A, Occhini D, Frassoni F: Autografting with Philadelphia chromosome negative mobilized hematopoietic progenitor cells in chronic myelogenous leukemia. Blood 1999;83:1534–1539.
- McGlave PB, De Fabritis P, Deisseroth A, Goldman J, Barnett M, Reiffers J, Simonsson B, Carella A, Aeppli D: Autologous transplants for chronic myelogenous leukaemia: Results from eight transplant groups. Lancet 1994;343:1486–1488.
Simonsson B, Oberg G, Bjoreman M, Bjorkholm M, Carneskog J, Gahrton G, Hast R, Karl H, Lanng-Nielsen J, Lofvenberg E, Malm C, Turesson I, Uden AM, Vilen L, Weis-Bjerrum O: Intensive treatment in order to minimize the Ph-positive clone in CML. Danish-Swedish CML Group. Bone Marrow Transplant 1996;17:63–64.
- Carella AM, Gaozza E, Raffo MR, Carlier P, Frassoni F, Valbonesi M, Lercari G, Sessarego M, Defferrari R, Guerrasio A, Saglio G, Canepa L, Gaetani GF, Occhini D: Therapy of acute phase chronic myelogenous leukemia with intensive chemotherapy, blood cell autotransplant and cyclosporine A. Leukemia 1991;5:517–521.
Hehlmann R, Heimpel H, Hossfeld DK, Hasford J, Kolb HJ, Loffler H, Pralle H, Queisser W, Hochhaus A, Tichelli A, Fett W, Schmitz N, Reiter A, Griesshammer M, Pfeifer W, Bumler M, Kamp T, Tobler A, Eimermacher H, Kuse R, Berger U, Ansari H: Randomized study of the combination of hydroxyurea and inteferon alpha versus hydroxyurea monotherapy during the chronic phase of chronic myelogenous leukemia (CML Study II). The German CML Study Group. Bone Marrow Transplant 1996;18(suppl 3):S21–S24.
- Guilhot F, Chastang C, Michallet M, Guerci A, Harousseau JL, Maloisel F, Bouabdallah R, Guyotat D, Cheron N, Nicolini F, Abgrall JF, Tanzer J: Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. N Engl J Med 1997;337:223–229.
- Long-term follow-up of the Italian trial of interferon-α versus conventional chemotherapy in chronic myeloid leukemia. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Blood 1998;92:1541–1548.
- Hasford J, Baccarani M, Hehlmann R, Anseri H, Tura S, Zuffa E: Interferon-alpha and hydroxyurea in early chronic myeloid leukemia: A comparative analysis of the Italian and German chronic myeloid leukemia trials with interferon-α. Blood 1996;87:5384–5391.
- Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. N Engl J Med 1994;330:820–825.
- Goto T, Nishikori M, Arlin Z, Gee T, Kempin S, Burchenal J, Strife A, Wisniewski D, Lambek C, Little C, Jhanwar S, Chaganti R, Clarkson B: Growth characteristics of leukemic and normal hematopoietic cells in Ph1+ chronic myelogenous leukemia and effect of intensive treatment. Blood 1982;59:793–808.
- Nielsen H, Nielsen JL, Karle H: Initial cytoreduction by mitoxantrone and cytarabine has no impact on the outcome of interferon-alfa-2b therapy in chronic myelogenous leukemia. Eur J Haematol 1992;49:67–70.
- Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, Niederwieser D, Resta D, Capdeville R, Zoellner U, Talpaz M, Druker B, Goldman J, O’Brien SG, Russell N, Fischer T, Ottmann O, Cony-Makhoul P, Facon T, Stone R, Miller C, Tallman M, Brown R, Schuster M, Loughran T, Gratwohl A, Mandelli F, Saglio G, Lazzarino M, Russo D, Baccarani M, Morra E: International STI571 CML Study Group: Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002;346:645–652.
- O’Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman JM, Kantarjian H, Taylor K, Verhoef G, Bolton AE, Capdeville R, Druker BJ, for the IRIS Investigators: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994–1004.
- Olsson-Stromberg U, Simonsson B, Ahlgren T, Bjorkholm M, Carlsson K, Gahrton G, Hast R, Lofvenberg E, Linder O, Ljungman P, Malm C, Paul C, Rodjer S, Turesson I, Uden AM, Wahlin A, Killander A, Wadman B, Westin J, Vikrot O, Zettervall O, Oberg G; Swedish CML Study Group: Comparison of busulphan, hydroxyurea and allogeneic bone marrow transplantation (BMT) in chronic myeloid leukemia: BMT prolongs survival. Hematol J 2004;5:462–466.
- Axdorph U, Stenke L, Grimfors G, Carneskog J, Hansen J, Linder O, Ljungman P, Lofvenberg E, Malm C, Simonsson B, Turesson I, Vilen L, Uden AM, Bjorkholm M, for the Swedish CML Group: Intensive chemotherapy in patients with chronic myelogenous leukaemia (CML) in accelerated or blastic phase – A report from the Swedish CML Group. Br J Haematol 2002;118:1048–1054.
- Hui CH, Goh KY, White D, Branford S, Grigg A, Seymour IF, Kwan YL, Walsh S, Hoyt R, Trickett A, Rudzki B, Ma DDF, To LB, Hughes TP: Successful peripheral blood stem cell mobilisation with filgrastim in patients with chronic myeloid leukaemia achieving complete cytogenetic response with imatinib, without increasing disease burden as measured by quantitative real-time PCR. Leukemia 2003;17:821–828.
- Kreuzer K-A, Klühs C, Baskaynak G, Movassaghi K, Dörken B, le Coutre P: Filgrastim-induced stem cell mobilization in chronic myeloid leukaemia patients during imatinib therapy: Safety, feasibility and evidence for an efficient in vivo purging. Br J Haematol 2004;124:195–199.
- Drummond MW, Marin D, Clark RE, Byrne JL, Holyoake TL, Lennard A, on behalf of the United Kingdom Chronic Myleoid Leukaemia (UK CML) Working Party: Mobilization of Ph chromosome-negative peripheral blood stem cells in chronic myeloid leukaemia patients with imatinib mesylate-induced complete cytogenetic remission. Br J Haematol 2003;123:479–483.
- Meng FY, Sun J, Liu QF, Xu D, Yang LJ, Song LL, Liu XL, Xu B, Zhou SY: Autogeneic peripheral blood hemopoietic stem cell transplantation for chronic myeloid leukemia with imatinib mesylate-induced negative Philadelphia chromosome (in Chinese). Di Yi Jun Yi Da Xue Xue Bao 2003;23:1301–1302, 1306.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.